Topic Listing for Pozen

Abstain8221 Accelerated Vesting Options Other Stock-based Awards
Accrued Expenses Accrued Expenses Including Contracted Costs
Administration Adverse Outcome Securities Class Action Lawsuits Been Filed
Aggregated Option Exercises Last Agreement
Amendment Amendment 333
Amendment Termination Amendment Tpp Profile Studies
Annual Cash Incentives Annual Meeting Stockholders Held 2005
Annual Meeting Stockholders Held 2006 Annual Meeting Stockholders Held 2007
Anti-takeover Provisions Charter Documents Delaware Law Prevent Delay Appendix
Appointment Independent Auditors Arranties Cceptance Ejection Ulk Rug Ubstance
Astrazeneca Audit Committee
Audit Committee Report Audit Fees
Audit Other Fees Audit-related Fees
Base Compensation Bonuses Base Salary
Because Not Believe Possible Convince Fda Reverse Conclusion Beneficial Ownership Reporting Compliance
Benefits Benefits Perquisites
Board Directors Recommends Vote Following Proposals Bonuses
Bulk Drug Substance Business Strategy
Cash Equivalents Cash Equivalents Concentration Credit Risk
Certain Deadlines 2006 Annual Meeting Certain Deadlines 2007 Annual Meeting
Certain Deadlines 2008 Annual Meeting Certain Relationships Related Transactions
Certain Relationships Related-party Transactions Certificate
Certification Change Management
Chapel Hill 2006 Pozen Inc Nasdaq Pozn Today Chapel Hill 2007 Pozen Inc Nasdaq Pozn Today
Chapel Hill 2008 8212 Pozen Inc Nasdaq Pozn Chapel Hill 2009
Chapel Hill 2009 8211 Pozen Inc Nasdaq Pozn Chapel Hill 2009 8212 Pozen Inc Nasdaq Pozn
Chedule C-1 Chief Executive Officer
Code Ethics Collaborative Arrangements
Collaborator Withdraw Support Cease Perform Work Product Candidates Collaborators Not Obtain Maintain Required Regulatory Approvals Product
Commercial Supply Bulk Drug Substance Commercialization
Committees Board Compared 2002
Compared 2003 Compared 2004
Compared 2005 Compared 2006
Compared 2008 Compensation
Compensation Chief Executive Officer Compensation Committee
Compensation Committee Interlocks Insider Participation Compensation Committee Report
Compensation Committee Report Executive Compensation Directors
Compensation Discussion Analysis Compensation Executive Officers
Compensation Non-employee Directors Compensation Plan
Competition Competitors Develop Commercialize Products Faster Superior Ours Commercial
Comprehensive Income Loss Comprehensive Loss
Concentration Credit Risk Conclusion Placebo
Confidential Separation Agreement General Release Confidentiality Publications Publicity
Consent Independent Registered Public Accounting Firm Consequences Change Control
Consequences Expiration Termination Consultant
Consulting Fee Contacts
Contents Contingencies
Contingent Annual Bonus Agreement Control Number
Controls Procedures Corporate Highlights
Corporate Information Counterparts
Critical Accounting Policies Estimates Currently Depend Future Parties Manufacture Product Candidates Manufacturers
Decide Pursue Commercialization Opportunities Future Products Ourselves Failure Deductibility 162
Definition Changes Deliverables
Departure Directors Certain Officers Election Appointment Compensatory Departure Directors Principal Officers Election Appointment
Depend Heavily Success Product Candidates Never Approved Commercial Depend Key Personnel Not Able Retain Employees Recruit
Description Description Existing Nycomed Product Deliverables
Description Ind Deliverables Description Specifications
Development Option License Agreement Development Program
Development Stage Directors Continuing Office
Directors Executive Officers Registrant Disclosure Patent Applications Communication
Dispute Resolution Documents Incorporated Reference
Ecitals Effectiveness Agreement
Efinitions Employee Termination Statement
Employees Employment Agreement
Employment Agreements Employment Change Control Arrangements
End 2006 Results Webcast End Results Webcast
Enforcement Patents Product Rights Territory Enforcement Rights
Entry Material Definitive Agreement Epresentations Arranties Imitation Arranty
Equipment Equity Compensation Plan
Equity Compensation Plans Equity Other Long-term Incentive Compensation
Erm Ermination Ernst Young Llp Fees Related 2004 2003
Estimates Exact Name Registrant Specified Charter
Executive Compensation Executive Officers
Executive Sessions Lead Independent Director Executive Sessions Lead Outside Director
Exhibits Exhibits Reports Form 8-k
Existing Nycomed Product Existing Nycomed Products
Explanatory Exploratory Programs
Factors Affect Results Fail Acquire Develop Commercialize Additional Products Product Candidates
Fail Develop Acquire Commercialize Additional Products Product Candidates Fair Value Financial Instruments
Federal Income Tax Consequences Financial Guidance
Financial Statements Exhibits Financial Statements Supplementary Data
For8221 Forfeitures Changes Stock
Form 10-k Form 10-q
Form Assignment Form Supply Agreement Sublicensees
Former Name Address Changed Since Last Report Forward-looking Information
Friday 2005 Friday 2008
Further Information Future Products Accepted Market
General Release Glaxosmithkline
Glaxosmithkline Gsk Governing Law Dispute Resolution
Grant Option Grants Plan-based Awards 2006
Greement Headings
Householding Annual Meeting Materials Iability
Imitrex Sumatriptan Succinate Tablets Income Taxes
Incurred Losses Since Inception Continue Incur Foreseeable Future Indemnification
Independence Directors Index
Initial Development Program Inspections Audits
Intellectual Property Internet Information
Inventions Agreement Inventions Ideas Products Etc Not Covered Agreement
Investment Investments
Isomer Option Ispute Esolution
John Barnhardt John Plachetka Peter Wise James Mauzey
Kristina Adomonis Leases
Legal Proceedings Liability
License Agreement License Agreements
License Grants Pozen Limitations Exclusivity
Liquidity Capital Resources List Countries Excluded Manufacturing License
Long Term Incentive Cash Award Agreement Lornoxicam
Lornoxicam Families Products Lornoxicam Injection
Lornoxicam Program Lornoxicam Substance
Managements Report Internal Control Over Financial Reporting Manufacturing
Market Common Stock Related Stockholder Matters Issuer Purchases Marshall Reese
Meetings Migraine
Migraine Market Overview Miscellaneous
Name Person Filing Proxy Statement Other Registrant Naproxen Sodium
Ndemnification Need Additional Funding Not Access Capital Unable Raise
Need Collaborate Parties Develop Commercialize Products Result Delays Need Maintain Current Agreements Enter Additional Parties Possess
Net Income Loss Per Share Net Loss Per Share
New Plan Benefits Nformation Icense
Nominating Corporate Governance Committee Nomination Election Directors
Nominees Election Director Term Nonqualified Deferred Compensation 2006
Nonqualified Stock Option Grant Not Receive Adequate Third-party Reimbursements Future Products Revenues
Notice Notice Annual Meeting Stockholders
Notice Period Notices
Nycomed Danmark Aps Obligations Commitments
Onfidentiality Onsequences Xpiration Ermination
Option Exercises Stock Vested 2006 Option Grant Nycomed
Option Grants Last Options
Other Events Other Fees
Other Matters Other Named Executive Officers
Other Plan Limitations Other Stock-based Awards
Overview Ownership
Pain Market Overview Part
Part Other Information Patent Costs
Patents Proprietary Information Pension Benefits 2006
Performance Units Performance-based Awards
Perquisites Phase
Philosophy Objectives Placebo
Post-employment Benefits Pozen
Pozen Inc Adopts Stockholder Rights Plan Pozen Limited
Pozen Receives Initial Fda Response Pa32540 Spa Ppi Nsaid Program
Pre-approval Policies Procedures Preferred Share Purchase Right
Principal Accounting Fees Services Principal Product Candidates
Principal Stockholders Procedures Policies Granting Equity-based Awards
Product Liability Lawsuits Successfully Brought Against Incur Substantial Products Accepted Market
Program Properties
Purpose Quality Regulations
Quantitative Qualitative Disclosures Market Risk Ratification Appointment Independent Auditors
Recent Accounting Pronouncements Recently Issued Accounting Pronouncements
Recitals Recommendation Board
Redeemable Preferred Stock Reese
Reference Agreement Registrants Telephone Number Including Area Code
Regulation Disclosure Reliance Collaborations Parties Develop Commercialize Products Subject Inherent
Remainder Page Intentionally Left Blank Remainder Page Intentionally Left Blank Signature Follows
Report Independent Registered Public Accounting Firm Representations Warranties
Representative Label Existing Nycomed Product Research Development Costs Including Clinical Trial Expenses
Restricted Stock Restricted Stock Unit Agreement
Restricted Stock Units Results
Results Operations Financial Condition Results Webcast
Retirement Savings Plan Revenue Recognition
Risks Related Potential Commercialization Product Candidates Role Executive Officers Determining Compensation
Royalties 1051 Net Sales Royalties Net Sales
Royalties Sublicense Revenues Royalty Adjustments
Sales Substantial Amounts Common Stock Public Market Depress Sales Substantial Amounts Common Stock Public Market Largest
Securities Exchange Act 1934 Securities Registered Pursuant Act
Security Ownership Certain Beneficial Owners Management Related Stockholder Services
Severance Change Control Benefits Shareholder Control Number8221
Shares Reserved Future Issuance Signature
Signatures Six-month Results
Sodium Amended Response Accepted Review Fda Status Expenses Related Product Candidates
Status Product Candidates Stock Awards
Stock Options Stock Options Other Incentive Awards
Stock Performance Graph Stock Plans
Stock Price Stock Price Volatile Result Significant Losses Stockholders
Stock Units Stock-based Compensation
Stockholder Communications Board Directors Stockholders Equity
Strict Construction Submission Matters Vote Security Holders
Subsequent Event Subsequent Events
Subsequent Events -the Evaluated Through 2009 Represents Date Supply Agreement
Supply Diligence Table Contents
Tax Accounting Implications Tax Fees
Tax Gross-up Ted Wood James Butler
Term Term Termination
Termination Material Definitive Agreement Termination Without Cause Non-renewal Term Good Reason
Thursday 2006 Thursday 2007
Time-based Stock Awards Trexima
Trexima Nda Track 2005 Submission Treximet
Twelve-month Results Types Awards Eligible Participants
Uality Egulations Unable Convince Fda Reverse Conclusion Not-approvable Letter 100
Unable Convince Fda Reverse Conclusion Not-approvable Letter 300 Unable Defend Patents Patent Infringement Lawsuits Against Generic
Unable Protect Patents Proprietary Rights Operate Business Without Unregistered Sales Equity Securities Proceeds
Upply Ulk Rug Ubstance Usc 1350
Valeant Pharmaceuticals North American Formerly Xcel Inc Vote Important Please Sign Date Reverse Side Card
Vote Required Approval Vote Required Election
Vote Today Ways Voting Rights
Waiver Warranties Acceptance Rejection Materials
What Reward William Hodges
Withheld8221 Withhold8221
Witness Whereof Intending Legally Bound Hereby Employee Pozen Xcel Pharmaceuticals Inc
Year-end Option Values 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki